ACRV1 and ovarian cancer: Collectively, our findings establish ZNF280A as a key regulator of metabolic reprogramming in OC through the CUX2–ACRV1–PI3K/AKT axis, highlighting this pathway as a potential therapeutic target in ovarian cancer.